Literature DB >> 20705311

Heparin sulphate D-glucosaminyl 3-O-sulfotransferase 3B1 plays a role in HBV replication.

Zhenzhen Zhang1, Xiang Liu, Juan Chen, Huaibin Su, Qiang Luo, Jia Ye, Ni Tang, Wenlu Zhang, WeiXian Chen, Ben C B Ko, Ailong Huang.   

Abstract

Hepatitis B virus infection is a worldwide epidemic and is closely associated with the development of hepatocellular carcinoma. Nevertheless, the molecular mechanisms of HBV infection and carcinogenesis remain elusive. Using a hepatocyte model of HBV infection and comparing the gene expression profiling analysis we found that heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3 B1 (HS3ST3B1,3-OST3-B) is down-regulated in the hepatocytes of chronic HBV infection model. HS3ST3B1 showed potent inhibitory effect on HBV replication. The inhibitory effect of HS3ST3B1 overexpression was lost upon gene silencing of HS3ST3B1 or when a catalytic inactive mutant of HS3ST3B1 was expressed. Our study revealed the anti-viral activity of HS3ST3B1 on HBV replication. It is conceivable that possible therapeutic applications of HBV infection could be devised by manipulating HS3ST3B1 activity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705311     DOI: 10.1016/j.virol.2010.07.030

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  S-phase arrest after vincristine treatment may promote hepatitis B virus replication.

Authors:  Lei Xu; Zeng Tu; Ge Xu; Jie-Li Hu; Xue-Fei Cai; Xing-Xing Zhan; Yu-Wei Wang; Yuan Huang; Juan Chen; Ai-Long Huang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1.

Authors:  Ji-Hua Ren; Ying Tao; Zhen-Zhen Zhang; Wei-Xian Chen; Xue-Fei Cai; Ke Chen; Ben C B Ko; Chun-Li Song; Long-Kuan Ran; Wan-Yu Li; Ai-Long Huang; Juan Chen
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

3.  Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.

Authors:  Vaibhav Tiwari; Jian Liu; Tibor Valyi-Nagy; Deepak Shukla
Journal:  J Biol Chem       Date:  2011-05-19       Impact factor: 5.157

Review 4.  Heparan sulfate 3-O-sulfation: a rare modification in search of a function.

Authors:  Bryan E Thacker; Ding Xu; Roger Lawrence; Jeffrey D Esko
Journal:  Matrix Biol       Date:  2013-12-19       Impact factor: 11.583

5.  Symmetry-related clustering of positive charges is a common mechanism for heparan sulfate binding in enteroviruses.

Authors:  Nigel J McLeish; Çigdem H Williams; Dimitrios Kaloudas; Merja M Roivainen; Glyn Stanway
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

6.  Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia.

Authors:  Susan McCormick; Qi He; Jordan Stern; Nikolai Khodarev; Ralph Weichselbaum; Christopher L Skelly
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

7.  ZEB2 inhibits HBV transcription and replication by targeting its core promoter.

Authors:  Qiao He; Wanyu Li; Jihua Ren; Yecai Huang; Ying Huang; Qin Hu; Juan Chen; Weixian Chen
Journal:  Oncotarget       Date:  2016-03-29

Review 8.  Diversity of heparan sulfate and HSV entry: basic understanding and treatment strategies.

Authors:  Vaibhav Tiwari; Morgan S Tarbutton; Deepak Shukla
Journal:  Molecules       Date:  2015-02-05       Impact factor: 4.411

Review 9.  Comprehensive Landscape of Heparin Therapy for COVID-19.

Authors:  Chen Shi; Wu Tingting; Jin-Ping Li; Mitchell A Sullivan; Cong Wang; Hanxiang Wang; Bin Deng; Yu Zhang
Journal:  Carbohydr Polym       Date:  2020-10-22       Impact factor: 10.723

Review 10.  Glyconanomaterials for Human Virus Detection and Inhibition.

Authors:  Noelia Losada-Garcia; Carla Garcia-Sanz; Alicia Andreu; Trinidad Velasco-Torrijos; Jose M Palomo
Journal:  Nanomaterials (Basel)       Date:  2021-06-26       Impact factor: 5.076

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.